Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Immunity & Ageing

Fig. 4

From: Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

Fig. 4

Summary of RSV/A and RSV/B Microneutralization Responses. RSV/A (a) and RSV/B (b) microneutralization antibody response kinetics in active vaccine and placebo recipients co-administered TIV based on the fold-rise in post-vaccination GMTs relative to baseline (GMRPost/Pre). Data are represented by the GMT and associated 95% CIs. The pooled day 0 GMT was log2 8.2 or GMT 294 (258–334 95% CI) for RSV/A MN and log2 8.1 or GMT 284 (239–336, 95% CI) for RSV/B MN

Back to article page